Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-18T07:42:12.397Z Has data issue: false hasContentIssue false

Ziprasidone and pulmonary embolism, report of a case

Published online by Cambridge University Press:  23 March 2020

S. Garcia Marin
Affiliation:
Centro Salud Mental Lorca, Adultos, Lorca, Spain
N. Martínez Pedrosa
Affiliation:
Hospital Vinalopó, Adultos, Elche, Spain
I. De Haro García
Affiliation:
Centro Salud Mental Lorca, Adultos, Lorca, Spain
M.D. Ortega García
Affiliation:
Centro de Salud Mental Cartagena, Adultos, Cartagena, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Several scientific studies support the relation between pulmonary embolism and antipsychotic treatment (acute or chronic). We present a case of possible association of venous thromboembolism (VTE) and ziprasidone.

Personal antecedents

Man, 55-year-old, with mild hypertension. He has neither toxics habits nor allergies. He does exercise every day. He started with behavioral and perception disorders during 9 months before being diagnosed of paranoid schizophrenia in 2002. He began with risperidone 3 mg per day and amisulpride 25 mg per day as hypnotic. It allowed a good development and he keeps stable since then. The treatment produced sedation and weight increase, so it was changed to ziprasidone 60 mg per day and later 40 mg per day. A few months ago, he was hospitalized with breathelessness that started suddenly two days before. After all diagnostic tests, he was diagnosed with pulmonary embolism and right leg VTE. His medical development was very positive and he must begin with acenocumarol (doses–depend) and support stockings.

Conclusion

As we know, since last 10 years, antipsychotic exposure significantly increases the risk of pulmonary embolism. Due to the lack of risk related factor in this case, it would point that reason. The increase related is about 50% of developing VTE and this increased risk similarly applies to first and second generation antipsychotics drugs. Despite that, there are more cases in olanzapine, clozapine and haloperidol treatments due to antiaggregatory action and antithrombotic effects. We present this case probably closely related with ziprasidone.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster Viewing: Schizophrenia and other psychotic disorders
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.